Proprietary AI analyst is now available

Dimed SA Valuation Multiples

Discover revenue and EBITDA valuation multiples for Dimed SA and similar public comparables like YSB, Great Tree Pharmacy, JZJ Chain Drugstore, DocMorris and more.

Dimed SA Overview

About Dimed SA

Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Its segments are divided into Retail, Wholesale and Corporate. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. The Wholesale segment is the distributor of drugs in Brazil. The Corporate segment includes Wholesale and Retail, as well as the subsidiary Lifar. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.


Founded

1967

HQ

Brazil

Employees

N/A

Sectors

Financials (LTM)

Revenue: $1B
EBITDA: $67M

EV

$530M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Dimed SA Financials

Dimed SA reported last 12-month revenue of $1B and EBITDA of $67M.

In the same LTM period, Dimed SA generated $67M in EBITDA and $29M in net income.

Revenue (LTM)


Dimed SA P&L

In the most recent fiscal year, Dimed SA reported revenue of $1B and EBITDA of $101M.

Dimed SA is profitable as of last fiscal year, with gross margin of 32%, EBITDA margin of 9%, and net margin of 2%.

See analyst estimates for Dimed SA
LTMLast FY202320242025202620272028
Revenue$1B$1B$879M$973M$1B
Gross Profit-$351M$271M$309M$351M
Gross Margin-32%31%32%32%
EBITDA$67M$101M$78M$84M$101M
EBITDA Margin6%9%9%9%9%
EBIT Margin4%5%4%4%5%
Net Profit$29M$25M$18M$21M$25M
Net Margin2%2%2%2%2%
Net Debt-$132M---

Financial data powered by Morningstar, Inc.

Dimed SA Stock Performance

Dimed SA has current market cap of $317M, and enterprise value of $530M.

Market Cap Evolution


Dimed SA's stock price is $2.13.

Dimed SA share price decreased by 10.1% in the last 30 days, and increased by 16.4% in the last year.

Dimed SA has an EPS (earnings per share) of $0.17.

See more trading valuation data for Dimed SA
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$530M$317M-6.9%-10.1%-26.3%16.4%$0.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Dimed SA Valuation Multiples

Dimed SA trades at 0.5x EV/Revenue multiple, and 7.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Dimed SA

EV / Revenue (LTM)


Dimed SA Financial Valuation Multiples

As of June 5, 2026, Dimed SA has market cap of $317M and EV of $530M.

Dimed SA has a P/E ratio of 11.1x.

LTMLast FY202320242025202620272028
EV/Revenue0.5x0.5x0.6x0.5x0.5x
EV/EBITDA7.9x5.3x6.8x6.3x5.3x
EV/EBIT10.9x10.4x16.0x13.5x10.4x
EV/Gross Profit-1.5x2.0x1.7x1.5x
P/E11.1x12.7x17.3x15.2x12.9x
EV/FCF-8.6x17.1x40.4x8.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Dimed SA Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Dimed SA Margins & Growth Rates

Dimed SA grew revenue by 17% but EBITDA decreased by 24% in the last fiscal year.

In the most recent fiscal year, Dimed SA reported gross margin of 32%, EBITDA margin of 9%, and net margin of 2%.

See estimated margins and future growth rates for Dimed SA

Dimed SA Margins

Last FY202420252026202720282029
Gross Margin32%32%32%-
EBITDA Margin9%9%9%6%
EBIT Margin5%4%5%5%
Net Margin2%2%2%3%
FCF Margin6%1%6%-

Dimed SA Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth17%11%12%17%
Gross Profit Growth-14%14%-
EBITDA Growth(24%)8%20%(24%)
EBIT Growth13%18%30%13%
Net Profit Growth34%14%18%37%
FCF Growth-(58%)370%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Dimed SA Operational KPIs

Dimed SA's Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Dimed SA's Rule of X is 47% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Dimed SA
LTMLast FY202320242025202620272028
Rule of 4022%23%---
Bessemer Rule of X46%47%---
S&M Expenses to Revenue-6%5%5%6%
G&A Expenses to Revenue-1%0%1%1%
Opex to Revenue-28%27%28%28%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Dimed SA Competitors

Dimed SA competitors include YSB, Great Tree Pharmacy, JZJ Chain Drugstore, DocMorris, Green Cross Health, Cawachi, Fangzhou, Profarma, MARX Biotech and d1000.

Most Dimed SA public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
YSB0.0x-2.0x-
Great Tree Pharmacy0.8x0.8x9.2x9.9x
JZJ Chain Drugstore0.7x-5.5x-
DocMorris0.4x0.4x(11.6x)(11.6x)
Green Cross Health0.8x-7.9x-
Cawachi0.2x0.2x4.6x-
Fangzhou0.2x0.2x25.2x19.8x
Profarma0.2x-4.1x-

This data is available for Pro users. Sign up to see all Dimed SA competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Dimed SA

When was Dimed SA founded?Dimed SA was founded in 1967.
Where is Dimed SA headquartered?Dimed SA is headquartered in Brazil.
Is Dimed SA publicly listed?Yes, Dimed SA is a public company listed on B3.
What is the stock symbol of Dimed SA?Dimed SA trades under PNVL3 ticker.
When did Dimed SA go public?Dimed SA went public in 1995.
Who are competitors of Dimed SA?Dimed SA main competitors include YSB, Great Tree Pharmacy, JZJ Chain Drugstore, DocMorris, Green Cross Health, Cawachi, Fangzhou, Profarma, MARX Biotech, d1000.
What is the current market cap of Dimed SA?Dimed SA's current market cap is $317M.
What is the current revenue of Dimed SA?Dimed SA's last 12 months revenue is $1B.
What is the current revenue growth of Dimed SA?Dimed SA revenue growth (NTM/LTM) is 16%.
What is the current EV/Revenue multiple of Dimed SA?Current revenue multiple of Dimed SA is 0.5x.
What is the current EBITDA of Dimed SA?Dimed SA's last 12 months EBITDA is $67M.
What is Dimed SA's EBITDA margin?Dimed SA's last 12 months EBITDA margin is 6%.
What is the current EV/EBITDA multiple of Dimed SA?Current EBITDA multiple of Dimed SA is 7.9x.
How many companies Dimed SA has acquired to date?Dimed SA hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Dimed SA has invested to date?Dimed SA hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Dimed SA

Lists including Dimed SA

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial